Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended		12 Months Ended	66 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Jun. 30, 2023
Cash flows from operating activities
Net loss	$ (78,779)	$ (91,585)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	269	277
Stock-based compensation	14,301	11,660
Issuance of PIK interest debt	1,772	1,713
Accrued interest on revenue interest financing liability	10,550	2,657
Amortization of debt discount	769	1,049
Other	1,157	874
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(3,633)	1,402
Accounts payable and accrued expenses (includes changes in related party amounts of $264 and $1,102, respectively)	(8,447)	2,865
Accrued clinical trial expenses		(1,061)
Accrued interest	73	88
Operating right-of-use assets and lease liabilities	99	(293)
Other long-term assets		(119)
Net cash used in operating activities	(61,869)	(70,473)
Cash flows from investing activities
Cash paid for property, plant and equipment	(220)	(495)
Net cash used in investing activities	(220)	(495)
Cash flows from financing activities
Proceeds from issuance of common stock from exercise of stock options	111
Net proceeds from underwritten public offering	141,390
Net proceeds from revenue interest financing transaction		95,446	$ 95,400
Net cash provided by financing activities	155,574	95,446
Net increase in cash and cash equivalents and restricted cash	93,485	24,478
Cash and cash equivalents and restricted cash - beginning of period	155,890	183,419	183,419
Cash and cash equivalents and restricted cash - end of period	249,375	207,897	$ 155,890	$ 249,375
Supplemental disclosure of cash flow information
Interest paid	5,310	2,920
Supplemental disclosure of noncash investing and financing activities
Inventory purchases included in accounts payable and accrued expenses	3,561
Property and equipment purchases included in accounts payable and accrued expenses		16
Settlement of ESPP liability in common stock	856	515
Settlement of 401(k) liability in common stock	456	254
Operating lease liabilities arising from obtaining right-of-use assets		$ 554
At-the-Market Offering Program
Cash flows from financing activities
Net proceeds from issuance of common stock	$ 14,073			$ 38,700